Fibromyalgia Clinical Trial
Official title:
An Open-label Feasibility Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome: A Pilot Study
Verified date | October 2019 |
Source | Eli Lilly and Company |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the possibility of conducting a larger study in adolescents with fibromyalgia syndrome.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | August 2010 |
Est. primary completion date | August 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 13 Years to 17 Years |
Eligibility |
Inclusion Criteria: - Meet criteria for juvenile primary fibromyalgia syndrome as defined by Yunus and Masi. - Have a score of greater than or equal to 40mm on item 3 of the Pediatric Pain Questionnaire at screening and treatment baseline. - Female patients must have a negative pregnancy test at baseline and must agree to abstain from sexual activity or use a reliable method of birth control. - Patients must be capable of swallowing study drug whole. - Patients must have venous access sufficient to allow blood sampling and be compliant with blood draws as per the protocol. Exclusion Criteria: - Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device, or off-label use of a drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. - Have pain symptoms related to traumatic injury, past surgery, structural bone or joint disease (such as osteoarthritis, bursitis, tendonitis), or regional pain syndrome that will interfere with the interpretation of outcome measures. - Have a confirmed current or previous diagnosis of rheumatoid arthritis, inflammatory arthritis, or infectious arthritis, or an autoimmune disease. - Have any primary Axis diagnosis OTHER than major depressive disorder (MDD) and/or generalized disorder (GAD) as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), currently or within the past year. Patients with specific phobias may participate in this study. - Have any lifetime DSM-IV Axis I diagnosis of psychosis, bipolar disorder, or schizoaffective disorder. - Have any DSM-IV Axis II disorder which, in the judgment of the investigator, would interfere with protocol compliance. - Have a history of substance abuse or dependence within the past year, excluding nicotine and caffeine. - Have a positive urine drug screen for any substances of abuse or excluded medication. - Have a family history of 1 or more first-degree relatives (parents or siblings) with diagnosed bipolar I disorder. - Have a significant suicide attempt within 1 year of screening or are currently at suicidal risk in the opinion of the investigator. - Have a weight less than 20 kg at any screening phase. - Have initiated, stopped, or changed the type or intensity of psychotherapy within 3 months prior to screening. - Have a history of seizure disorder (other than febrile seizures). - Have abnormal thyroid-stimulating hormone (TSH) concentrations. Patients with hypothyroidism who have been treated on a stable dose of thyroid supplement for at least the past 3 months and have medically appropriate TSH concentrations, and are clinically euthyroid may participate in the study. - Have acute liver injury or sever cirrhosis. - Have previously taken duloxetine. - Have a serious or unstable medical illness. - Have initiated or discontinued hormone therapy within the previous 3 months. |
Country | Name | City | State |
---|---|---|---|
United States | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Canton | Ohio |
United States | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cincinnati | Ohio |
United States | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Fairfield | Connecticut |
United States | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Oklahoma City | Oklahoma |
United States | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Phoenix | Arizona |
United States | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Portland | Oregon |
United States | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Saint Louis | Missouri |
United States | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Salt Lake City | Utah |
United States | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Staten Island | New York |
Lead Sponsor | Collaborator |
---|---|
Eli Lilly and Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of enrollment | 6 months of enrollment | ||
Primary | Rate of retention | 12 weeks of treatment | ||
Secondary | Change in score from baseline to endpoint on the Pediatric Pain Questionnaire (PPQ) | Baseline, 12 weeks | ||
Secondary | Change in score from baseline to endpoint on the Brief Pain Inventory (BPI) modified short form severity | Baseline, 12 weeks | ||
Secondary | Change in score from baseline to endpoint on the Clinical Global Impression of Severity, overall (CGI-Severity: overall) scale | Baseline, 12 weeks | ||
Secondary | Endpoint score of Patient Global Impression of Improvement (PGI-I) scale | 12 weeks | ||
Secondary | Change in score from baseline to endpoint on the Functional Disability Inventory - child version (FDI-child) scale | Baseline, 12 weeks | ||
Secondary | Change in score from baseline to endpoint on the Functional Disability Inventory - parent version (FDI-parent) scale | Baseline, 12 weeks | ||
Secondary | Change in score from baseline to endpoint on the Clinical Global Impression of Severity for Mental Illness (CGI-mental illness) scale | Baseline, 12 weeks | ||
Secondary | Change in score from baseline to endpoint on the Children's Depression Inventory (CDI) | Baseline, 12 weeks | ||
Secondary | Change in score from baseline to endpoint on the Multidimensional Anxiety Scale for Children (MASC) | Baseline, 12 weeks | ||
Secondary | Columbia Suicide-Severity Rating Scale (CSSRS) | During 12 weeks of treatment | ||
Secondary | Change in score from baseline to endpoint on the Pediatric Quality of Life Inventory - teen report (PedsQL) | Baseline, 12 weeks | ||
Secondary | Number of patients with treatment emergent abnormal laboratory values | During 12 weeks of treatment | ||
Secondary | Change from baseline to endpoint in blood pressure | Baseline, 12 weeks | ||
Secondary | Change from baseline to endpoint in heart rate | Baseline, 12 weeks | ||
Secondary | Change from baseline to endpoint in weight | Baseline, 12 weeks | ||
Secondary | Change from baseline to endpoint in height | Baseline, 12 weeks | ||
Secondary | Number of patients with treatment emergent abnormal electrocardiogram | During 12 weeks of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05659862 -
Digitally Assisted Behavioral Physical Activity Intervention in Fibromyalgia
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT03042728 -
Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program
|
N/A | |
Recruiting |
NCT06097091 -
Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia
|
N/A | |
Recruiting |
NCT04554784 -
Effectiveness of Bowen Therapy for Pain Management in Patients With Fibromyalgia
|
N/A | |
Completed |
NCT03300635 -
Metabolism, Muscle Function and Psychological Factors in Fibromyalgia
|
N/A | |
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT03166995 -
Postural Exercises in Women With Fibromyalgia
|
N/A | |
Completed |
NCT03227952 -
Sensory Stimulation in Fibromyalgia
|
N/A | |
Recruiting |
NCT06237595 -
Vagus Nerve Stimulation in Fibromyalgia
|
N/A | |
Completed |
NCT01888640 -
Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)
|
N/A | |
Completed |
NCT03641495 -
Pain Education and Therapeutic Exercise for Fibromyalgia
|
N/A | |
Recruiting |
NCT05581628 -
FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
|
||
Active, not recruiting |
NCT05128162 -
Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
|
Phase 2 | |
Completed |
NCT04674878 -
Comparison of Muscle Energy Techniques and Breathing Exercises for Functional Improvement in Fibromyalgia
|
N/A | |
Active, not recruiting |
NCT04084795 -
Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia
|
N/A | |
Completed |
NCT03129906 -
Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients
|
N/A | |
Completed |
NCT05058911 -
Exposure-based Cognitive Behavior Therapy vs Traditional Cognitive Behavior Therapy for Fibromyalgia
|
N/A | |
Recruiting |
NCT04571528 -
Effectiveness of VIRTUAL FIBROWALK STUDY
|
N/A | |
Recruiting |
NCT04571853 -
New Educational Tool for FM
|
N/A |